meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine

Action and Spectrum

Actions and Spectrum: 

Actions: 

Formation of bactericidal antibodies after administration of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine which provides immunity against meningococcal disease caused by Neisseria meningitidis which can be prevented via directing the formed antibodies towards the serogroups A, C, Y, and W-135. 

Spectrum: 

meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine is used as an active immunization procedure to develop antibodies against meningococcal disease. 

Drug Interaction

Adverse Reaction

Frequency defined 

>10% 

Children aged 2-9 year 

• Injection site pain (38.6%) 
• Injection site erythema (22.6%) 
• Malaise (21.1%) 
• Myalgia (20.1%) 
• Injection site swelling (13.8%) 
• Headache (12.5%) 

Adolescents aged 10-17 year 

• Injection site pain (45.2%) 
• Myalgia (35.3%) 
• Headache (30.2%) 
• Malaise (26%) 

Adults aged 18-55 year 

• Injection site pain (41.9%) 
• Myalgia (35.6%) 
• Headache (29%) 
• Malaise (22.9%) 

Adults aged 56 year or older 

• Injection site pain (25.5%) 
• Myalgia (21.9%) 
• Headache (19%) 
• Malaise (14.5%) 

1-10% 

Children aged 2-9 year 

• Fever (1.9%) 

Adolescents aged 10-17 year 

• Injection site swelling (5.4%) 
• Injection site erythema (5%) 
• Fever (1.4%) 

Adults aged 18-55 year 

• Injection site erythema (5.1%) 
• Injection site swelling (4.3%) 
• Fever (1.4%)

Adults aged 56 year or older 

• Injection site erythema (5.2%) 
• injection site swelling (4.5%) 
• Fever (2.1%)

1-10%  

Children aged 2-9 year 

• Injection site erythema (3.1%) 
• Malaise (1.8%) 
• Injection site swelling (1.4%) 

Adolescents aged 10-17 year 

• Malaise (2.2%) 
• Headache (1.8%) 
• Myalgia (1.6%) 
• Injection site pain (1.4%) 

Adults aged 18-55 year 

• Myalgia (3.6%) 
• Headache (2.9%) 
• Malaise (2.9%) 
• Injection site pain (1.9%) 

Adults aged 56 year or older 

• Myalgia (1.6%) 
• Malaise (1.4%)

<1%  

Children aged 2-9 year 

• Injection site pain (0.6%) 
• Myalgia (0.4%) 

Adolescents aged 10-17 year 

• Injection site erythema (0.4%) 
• Fever (0.4%) 
• Injection site swelling (0.2%) 

Adults aged 18-55 year 

• Injection site erythema (0.3%) 
• Injection site swelling (0.2%) 
• Fever (0.1%) 

Adults aged 56 year or older 

• Injection site pain (0.7%) 
• Headache (0.7%) 
• Injection site erythema (0.2%) 
• Fever (0.2%) 

Black Box Warning

Black Box Warning: 

meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine is administered only via IM. It should be kept out of reach of children. 

Contraindication / Caution

Contraindication/Caution: 

Contraindications 

• Allergic reactions 

Cautions 

• Acute allergic reactions 
• Syncope 
• Guillian-Barre syndrome 
• Immunosuppressive treatment 
• Coadministration with other vaccines 
• Altered immunocompetence 

Pregnancy / Lactation

Pregnancy consideration:  

No data is available regarding the administration of the drug during pregnancy. 

Breastfeeding warnings:  

No data is available regarding the excretion of drug in breast milk. 

Pregnancy category: 

Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester. 

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. 

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    

Category N: No data is available for the drug under this category. 

Pharmacology

Pharmacology: 

meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine is conjugated to tetanus toxoid protein carrier to give immunity against meningococcal disease. Formation of bactericidal antibodies after administration of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine, which provides immunity against meningococcal disease caused by Neisseria meningitidis which can be prevented via directing the formed antibodies towards the serogroups A, C, Y, and W-135.  

Pharmacodynamics: 

Antibodies once formed after meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine can give protection against meningococcal disease that is caused due to Neisseria meningitidis. 

Pharmacokinetics: 

Limited data available. Onset of action post vaccination occurs via seroconversion is after 1 month where duration of its action that is antibody waning can seen upto 5 years following primary vaccination where booster dose is recommended to make antibodies persist in the body and this antibody waning may vary with special product and among serogroups. 

Adminstartion

Administration: 

meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine is carried out its immunization by intramuscular route only. Injection site recommended in infants is anterolateral aspect of thigh and after 12 months children the injection site can also be deltoid muscle. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine 

Pronounced: muh-nin-jeh-KOK-ul  A-C-Y and -W paw-lee-sak-uh-yahyd the-tuh-nuhs tok-soyd kun-juh-gayt vak-seen  

Why do we use meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine? 

meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine is used in the immunization via IM injection to give protection against meningococcal disease that is caused due to Neisseria meningitidis. This can also be used as a booster dose after primary vaccination after 10 years of age or above 12 years of age administered to the persons with high risk.